From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.

PCP or phencyclidine was discovered in 1956 and soon became a popular street drug. Dissociatives including PCP, ketamine, and dextromethorphan have been used non-medically for their mind-altering effects for over 60 years. Many of these compounds have also been used clinically and in legitimate research. At least 14 derivatives of PCP were sold for non-medical and illict use from the late 1960s until the 1990s. With the advent of the Internet, the drug market underwent a dramatic evolution. While initially gray-market chemical vendors offering dextromethorphan and ketamine thrived, most recently the market has shifted to legal high and online-based research chemical vendors. Starting with the first dissociative research chemical, 4-MeO-PCP in 2008, the dissociative research chemical market has rapidly evolved and currently comprises at least 12 dissociatives, almost half of which were unknown in the scientific literature prior to their introduction. Several of these, including methoxetamine, have reached widespread use internationally. A historical account of non-medical use of over 30 dissociative compounds was compiled from a diverse collection of sources. The first complete portrait of this underground market is presented along with the relevant legal, technological, and scientific developments which have driven its evolution.

[1]  R. Burns,et al.  Phencyclidine use among youth: history, epidemiology, and acute and chronic intoxication. , 1978, NIDA research monograph.

[2]  G. Albers,et al.  Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke , 1995 .

[3]  J. Ramsey,et al.  Novel drugs--novel branding. , 2012, QJM : monthly journal of the Association of Physicians.

[4]  M. Peet,et al.  Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague–Dawley rats , 2010, Pharmacology Biochemistry and Behavior.

[5]  K. Brady,et al.  Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey , 1981, Pharmacology Biochemistry and Behavior.

[6]  M. Weller,et al.  Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.

[7]  M. Coppola,et al.  Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? , 2013, Medical hypotheses.

[8]  M. Klein,et al.  Abuse Liability Assessment of Neuroprotectants , 1999, Annals of the New York Academy of Sciences.

[9]  Jeanine A Ward,et al.  Methoxetamine: a novel ketamine analog and growing health-care concern , 2011, Clinical toxicology.

[10]  M. Meyer,et al.  Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn , 2013, Analytical and Bioanalytical Chemistry.

[11]  J Robles,et al.  PCP: a review of synthetic methods for forensic clandestine investigation. , 1993, Forensic science international.

[12]  F. Hammerschmidt,et al.  NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. , 2009, Bioorganic & medicinal chemistry.

[13]  F. Peters,et al.  New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. , 2008, Journal of mass spectrometry : JMS.

[14]  O. Corazza,et al.  From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine , 2013, CNS neuroscience & therapeutics.

[15]  V. Setola,et al.  The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor , 2013, PloS one.

[16]  TOXIC PSYCHOSIS DUE TO DEXTROMETHORPHAN , 1967 .

[17]  T. Noguchi,et al.  Determination of 1-(1-phenylcyclohexyl) pyrrolidine (PHP) in postmortem specimens: a case report. , 1979, Clinical toxicology.

[18]  M. Coppola,et al.  Methoxetamine: from drug of abuse to rapid-acting antidepressant. , 2012, Medical hypotheses.

[19]  Mohler Jl Abnormal tests don't change smoking habits. , 1980 .

[20]  J. Olney,et al.  Neuronal Vacuolization and Necrosis Induced by the Noncompetitive N-methyl-d-aspartate (NMDA) Antagonist MK(+)801 (Dizocilpine Maleate): A Light and Electron Microscopic Evaluation of the Rat Retrosplenial Cortex , 1993, Experimental Neurology.

[21]  E. Cone,et al.  Phencyclidine analogs and precursors: rotarod and lethal dose studies in the mouse. , 1984, The Journal of pharmacology and experimental therapeutics.

[22]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[23]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[24]  R. Garey,et al.  PCP (phencyclidine): an update. , 1979, Journal of psychedelic drugs.

[25]  G. Chen,et al.  The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. , 1959, The Journal of pharmacology and experimental therapeutics.

[26]  L. Iversen,et al.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Dargan,et al.  Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. , 2014, Drug testing and analysis.

[28]  K. Lees,et al.  Clinical experience with excitatory amino acid antagonist drugs. , 1995, Stroke.

[29]  D. Lodge,et al.  Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. , 1985, European journal of pharmacology.

[30]  G. Chen,et al.  The pharmacology of 2-(ethylamino)-2-(2-thienyl)-cyclohexanone-HCl (CI-634). , 1969, The Journal of pharmacology and experimental therapeutics.

[31]  J. Olney,et al.  Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity , 1998, Neuropsychopharmacology.

[32]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[33]  David R. Spiegel,et al.  Psychosis Induced by the Interaction of Memantine and Amantadine: Lending Evidence to the Glutamatergic Theory of Schizophrenia , 2007 .

[34]  V. H. Maddox,et al.  THE SYNTHESIS OF PHENCYCLIDINE AND OTHER 1-ARYLCYCLOHEXYLAMINES. , 1965, Journal of medicinal chemistry.

[35]  J. P. Morgan,et al.  The dusting of America: the image of phencyclidine (PCP) in the popular media. , 1980, Journal of psychedelic drugs.

[36]  R. Mcquinn,et al.  Structure-activity relationship studies of phencyclidine derivatives in rats. , 1984, The Journal of pharmacology and experimental therapeutics.

[37]  J. Wallach,et al.  Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. , 2014, Drug testing and analysis.

[38]  J. Olney,et al.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.

[39]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[40]  JOSEPH ZILBER,et al.  issue 1 , 2020, JORDANIAN JOURNAL OF ENGINEERING AND CHEMICAL INDUSTRIES (JJECI).

[41]  C. Man,et al.  'Street ketamine'-associated bladder dysfunction: a report of ten cases. , 2007, Hong Kong medical journal = Xianggang yi xue za zhi.

[42]  K. Rentsch,et al.  Ketamine-like effects after recreational use of methoxetamine. , 2012, Annals of emergency medicine.

[43]  W. Buchwald,et al.  Phencyclidine: Detection and measurement of toxic precursors and analogs in lllicit samples. , 1980, Journal of analytical toxicology.

[44]  T. Litovitz,et al.  Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010 , 2011, Clinical toxicology.

[45]  M. Schmutz,et al.  1 – Selfotel (CGS19755) , 1997 .

[46]  A. Shulgin Drugs of abuse in the future. , 1975, Clinical toxicology.

[47]  Marion Kee,et al.  Analysis , 2004, Machine Translation.

[48]  G. Bigelow,et al.  Guidelines and methodological reviews concerning drug abuse liability assessment. , 2003, Drug and alcohol dependence.

[49]  S. Nordt "DXM": A New Drug of Abuse? , 1998, Annals of emergency medicine.

[50]  E. Lear INTRAVENOUS ANESTHESIA ..... a survey of newer agents , 1968, Anesthesia and analgesia.

[51]  A. Giannini,et al.  A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. , 1982, Journal of toxicology. Clinical toxicology.

[52]  E. Domino,et al.  Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man , 1965, Clinical pharmacology and therapeutics.

[53]  K. Shahzad Understanding mechanisms of Ketamine-induced human urinary tract damage , 2011 .

[54]  J. Kamenka,et al.  Conformational determination of phencyclidine derivatives for a structure activity correlation , 1979 .

[55]  R. Gupta,et al.  Phencyclidine: patterns seen in street drug analysis. , 1976, Clinical toxicology.

[56]  P. Herrling,et al.  List of Drugs in Development for Neurodegenerative Diseases , 2004, Neurodegenerative Diseases.

[57]  T. Nabeshima,et al.  Phencyclidine-induced discriminative stimulus is mediated via phencyclidine binding sites on the N-methyl-d-aspartate receptor-ion channel complex, not via sigma1 receptors , 2001, Behavioural Brain Research.

[58]  G. Albers,et al.  Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. , 1999, Stroke.

[59]  K. Bailey Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. , 1978, Journal of pharmaceutical sciences.

[60]  J. Casale,et al.  The Characterization of 2-( 3-Methoxyphenyl )-2-( ethylamino ) cyclohexanone ( Methoxetamine ) , 2012 .

[61]  H. Hirbec,et al.  Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. , 2006, CNS drug reviews.

[62]  J. Meyer,et al.  A NEW DRUG CAUSING SYMPTOMS OF SENSORY DEPRIVATION Neurological, Electroencephalographic and Pharmalogical Effects of Sernyl , 1959 .

[63]  R. Degkwitz [DEXTROMETHORPHAN (ROMILAR) AS AN INTOXICATING AGENT]. , 1964, Der Nervenarzt.

[64]  Yueh-Ching Chou,et al.  Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan , 1999, Brain Research.

[65]  M. Lazdunski,et al.  CHEMICAL SYNTHESIS AND MOLECULAR PHARMACOLOGY OF HYDROXYLATED 1-(1-PHENYLCYCLOHEXYL)PIPERIDINE DERIVATIVES , 1982 .

[66]  E. Domino Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists , 1992, Journal of psychopharmacology.

[67]  K. Jansen Ketamine: Dreams and Realities , 2004 .

[68]  J. Woods,et al.  Discriminative stimulus effects of narcotics: evidence for multiple receptor-mediated actions. , 1981, Life sciences.

[69]  R. Schwartz Adolescent Abuse of Dextromethorphan , 2005, Clinical pediatrics.

[70]  L. Dods Observations on certain aspects of the cyclic vomiting syndrome. , 1935 .

[71]  Derek Partridge,et al.  The Soft Machine , 2011 .

[72]  Andrew Grace The Hive , 2015 .

[73]  F. Vollenweider,et al.  Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) , 2010, PloS one.

[74]  New street analogs of phencyclidine , 1992 .

[75]  A C Moffat,et al.  Drugs of abuse. , 2000, Science & justice : journal of the Forensic Science Society.

[76]  P. Dargan,et al.  Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine , 2012, European Journal of Clinical Pharmacology.

[77]  Siegel Rk Phencyclidine and ketamine intoxication: a study of four populations of recreational users. , 1978 .

[78]  J. Smialek,et al.  Cyclohexamine (“Rocket Fuel”)-Phencyclidine's Potent Analog , 1979 .

[79]  R. Monastero,et al.  Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[80]  A. Andrews UNITED STATES COURT OF APPEALS , 1998 .

[81]  Y. Yoo,et al.  A fatality due to injection of tiletamine and zolazepam. , 2000, Journal of analytical toxicology.

[82]  D. MacLean,et al.  Illicit synthesis of phencyclidine (PCP) and several of its analogs. , 1976, Clinical toxicology.

[83]  R. Petersen,et al.  Phencyclidine: an overview. , 1978, NIDA research monograph.

[84]  P. Dargan,et al.  Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation , 2012, Clinical toxicology.

[85]  K. Jellinger Ionotropic Glutamate Receptors as Therapeutic Targets , 2004 .

[86]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[87]  A. General,et al.  UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT , 2015 .

[88]  H. Sandler,et al.  Fatal intoxication by dextromethorphan: a report on two cases. , 1988, Forensic science international.

[89]  J. Wallach,et al.  From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. , 2013, Journal of analytical toxicology.

[90]  A. Kalir,et al.  1-Phenycycloalkylamine derivatives. II. Synthesis and pharmacological activity. , 1969, Journal of medicinal chemistry.

[91]  E. Domino Taming the Ketamine Tiger , 2010, Anesthesiology.

[92]  J. Inciardi,et al.  A critical review of pentazocine abuse. , 1971, HSMHA health reports.

[93]  R. Tampi,et al.  A systematic review of off-label uses of memantine for psychiatric disorders , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[94]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[95]  R. Deluca,et al.  A fatality related to the veterinary anesthetic telazol. , 1999, Journal of analytical toxicology.

[96]  M. Rogawski,et al.  Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. , 1990, Journal of Medicinal Chemistry.

[97]  A. Giannini,et al.  Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. , 1985, Journal of toxicology. Clinical toxicology.

[98]  Emcdda Annual Report 2009: the state of the drugs problem in Europe , 2009 .

[99]  List of Drugs in Development for Neurodegenerative Diseases , 2007, Neurodegenerative Diseases.

[100]  K. Rice,et al.  The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. , 1989, Molecular pharmacology.

[101]  J. Ballinger,et al.  GLC Quantitation of 1-Piperidinocyclohexanecarbonitrile (PCC) in Illicit Phencyclidine (PCP) , 1979 .

[102]  M. Lazdunski,et al.  Biochemical properties of the brain phencyclidine receptor. , 1982, European journal of pharmacology.

[103]  E. Domino History and pharmacology of PCP and PCP-related analogs. , 1980, Journal of psychedelic drugs.

[104]  C. Haertzen,et al.  Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. , 1986, The Journal of pharmacology and experimental therapeutics.

[105]  E. Sellers,et al.  Assessing Abuse Liability During Drug Development: Changing Standards and Expectations , 2008, Clinical pharmacology and therapeutics.

[106]  F. Greifenstein,et al.  A STUDY OF A 1‐ARYL CYCLO HEXYL AMINE FOR ANESTHESIA* , 1958, Anesthesia and analgesia.

[107]  Alan D. Woolf,et al.  Abuse of Telazol: An Animal Tranquilizer , 2001, Journal of toxicology. Clinical toxicology.

[108]  C. E. Reier Ketamine--"dissociative agent" or hallucinogen? , 1971, The New England journal of medicine.